Meningitis Outbreak at Kent University Linked to 2015 Vaccine Policy Gap
A tragic meningitis outbreak at the University of Kent has resulted in the deaths of two students and left 20 others requiring medical treatment, raising urgent questions about a vaccine policy decision made over a decade ago. The affected students belong to a generation that was not routinely vaccinated against meningococcal group B disease, despite the availability of the Bexsero vaccine since 2013 and its inclusion in the UK's national immunisation schedule in 2015.
Vaccine Rollout Limitations and Economic Considerations
The Bexsero vaccine was introduced to protect against meningococcal group B, a serious bacterial infection that can lead to meningitis and sepsis. However, the rollout was restricted to babies born after July 2015, with no catch-up programme implemented for older children. This decision was based on the Joint Committee on Vaccination and Immunisation (JCVI) assessment that the benefits of a wider rollout did not meet the economic threshold at the time.
Critics argue that this policy failed to account for the heightened risk in university settings, where close living quarters and social interactions significantly increase the transmission of meningococcal bacteria. The outbreak at the University of Kent underscores this vulnerability, as students in such environments are particularly susceptible to rapid disease spread.
Health Secretary's Response and Future Implications
In response to the outbreak, Health Secretary Wes Streeting has publicly stated that meningitis cases may well continue to rise unless immediate action is taken. He has directed the JCVI to re-examine eligibility criteria for meningitis vaccines, emphasizing the need for policy changes to protect current students. Without intervention, this cohort will remain without routine protection until at least 2033, leaving them at ongoing risk.
The situation highlights a critical gap in public health planning, where economic evaluations may have overshadowed potential risks in high-transmission environments like universities. As the JCVI reviews its stance, there is growing pressure to implement a catch-up vaccination programme to prevent further tragedies and ensure comprehensive coverage for all at-risk age groups.
